In connection with the Reneo and Anteris License Agreements, the Company has received equity interests representing a minority equity interest in each investee. In each case, the Company’s investment is measured at cost less impairment, adjusted for any changes in observable prices, because the Company owns less than 20% of the voting equity and does not have the ability to exercise significant influence over the investees. The investments were initially recognized at fair value and are classified as long-term investments in the Company’s Consolidated Balance Sheets.

As of December 31, 2020, the Company’s equity investments without readily determinable fair values assessed under the measurement alternative consist of the following:

	March 31, 2021		December 31, 2020
Reneo common stock	$	2,480	$	2,480
Anteris preferred stock		4,245		4,245
Total	$	6,725	$	6,725

No adjustments have been made to the value of the Company’s investment in either Reneo or Anteris since their initial measurement either due to impairment or based on observable price changes.